Monthly PubMed Review

Home » Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer 

April 2019

Would you like to receive our monthly PubMed Review in your inbox?

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Circulating Inflammation Proteins Associated With Lung Cancer in African Americans. Meaney CL1, Mitchell KA1, Zingone A1, et al. J Thorac Oncol. 2019 Apr 3. pii: S1556-0864(19)30269-2. doi: 10.1016/j.jtho.2019.03.014. [Epub ahead of print]

 

Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a.

Tang H1, Han X2, Li M1, Li T1, Hao Y3. Biochimie. 2019 Apr 25;162:134-143. doi: 10.1016/j.biochi.2019.04.019. [Epub ahead of print]

 

Plakophilin 1 is methylated and has a tumor suppressive activity in human lung cancer. Haase D1, Cui T1, Yang L1, Ma Y1, Liu H2, Theis B1, Petersen I1, Chen Y3. Exp Mol Pathol. 2019 Apr 1;108:73-79. doi: 10.1016/j.yexmp.2019.04.001. [Epub ahead of print]

SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING

Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure. Zhou J1, Zhao C2, et al. Thorac Cancer. 2019 Apr;10(4):957-965. doi: 10.1111/1759-7714.13035. Epub 2019 Mar 18.

 

Improving Lung Cancer Screening Access for Individuals With Serious Mental Illness. Flores EJ1, Park ER2, Irwin KE2. J Am Coll Radiol. 2019 Apr;16(4 Pt B):596-600. doi: 10.1016/j.jacr.2018.12.045.

 

Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists. Kashima J1,2, Kitadai R3, Okuma Y4,5. Cancers (Basel). 2019 Apr 29;11(5). pii: E599. doi: 10.3390/cancers11050599.

 

The Patient Perspective on Lung Cancer Screening and Health Disparities. Borondy Kitts AK1. J Am Coll Radiol. 2019 Apr;16(4 Pt B):601-606. doi: 10.1016/j.jacr.2018.12.028.

 

Improved False-Positive Rates and the Overestimation of Unintended Harm from Lung Cancer Screening. Karush J1,2, Arndt A3, Shah P4, et al. Lung. 2019 Apr 12. doi: 10.1007/s00408-019-00217-4. [Epub ahead of print]

 

Using a Dedicated Interventional Pulmonology Practice Decreases Wait Time Before Treatment Initiation for New Lung Cancer Diagnoses. Benn BS1, Parikh M2, Tsau PH3, Seeley E4, Krishna G4,5.

Lung. 2019 Apr;197(2):249-255. doi: 10.1007/s00408-019-00207-6. Epub 2019 Feb 19.

 

Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. Pinto JA1, Raez LE2, Oliveres H3, Rolfo CC4. Expert Opin Biol Ther. 2019 Apr 19:1-7. doi: 10.1080/14712598.2019.1610380. [Epub ahead of print]

 

Disparities in Lung Cancer Screening Availability: Lessons from Southwest, Virginia. Martin AN1, Kozower BD2, Camacho F3, Hassinger T4, Anderson RT3, Yao N3. Ann Thorac Surg. 2019 Apr 2. pii: S0003-4975(19)30429-1. doi: 10.1016/j.athoracsur.2019.03.003. [Epub ahead of print]

 

Challenges and Opportunities for Lung Cancer Screening in Rural America. Odahowski CL1, Zahnd WE2, Eberth JM3. J Am Coll Radiol. 2019 Apr;16(4 Pt B):590-595. doi: 10.1016/j.jacr.2019.01.001.

NSCLC SURGERY

No drain after thoracoscopic major lung resection for cancer helps preserve the physical function.

Ueda K1, Haruki T2, Murakami J2, Tanaka T2, Hayashi M2, Hamano K2. Ann Thorac Surg. 2019 Apr 5. pii: S0003-4975(19)30493-X. doi: 10.1016/j.athoracsur.2019.03.018. [Epub ahead of print]

 

Surgical outcome of pulmonary artery reconstruction using the expanded polytetrafluoroethylene patch in patients with lung cancer. Yoshino M1, Saitoh Y2, Chiyo M2, Hoshino H3, Sekine Y3, Wada H4, Suzuki H4, Yoshino I4. Surg Today. 2019 Apr 1. doi: 10.1007/s00595-019-01803-y. [Epub ahead of print]

 

Competing Risk Analysis in Lung Cancer Patients Over 80 Years Old Undergoing Surgery. Hino H1, Karasaki T2, Yoshida Y3, et al. World J Surg. 2019 Apr 1. doi: 10.1007/s00268-019-04982-4. [Epub ahead of print]

 

The impact of emphysema on surgical outcomes of early-stage lung cancer: a retrospective study.

Sato S1, Nakamura M2, Shimizu Y2, Goto T2, Koike T2, Ishikawa H3, Tsuchida M2. BMC Pulm Med. 2019 Apr 4;19(1):73. doi: 10.1186/s12890-019-0839-1.

 

Preoperative thoracic muscle area on computed tomography predicts long-term survival following pneumonectomy for lung cancer. Troschel FM1, Kuklinski MW1, Knoll SJ2, Best TD1,3, Muniappan A2, Gaissert HA2, Fintelmann FJ1. Interact Cardiovasc Thorac Surg. 2019 Apr 1;28(4):542-549. doi: 10.1093/icvts/ivy280.

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy. Li H1, Wang C2, Wang Z1, et al. Lung Cancer. 2019 Apr;130:42-49. doi: 10.1016/j.lungcan.2019.02.001. Epub 2019 Feb 2.

 

Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Zhao S#1, Ren S#1, Jiang T#1, et al. Cancer Immunol Res. 2019 Apr;7(4):630-643. doi: 10.1158/2326-6066.CIR-17-0640. Epub 2019 Feb 12.

 

Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients. Lau YY1, Gu W2, Ho YY2, Hong Y2, Zhang X2, Urban P3. Cancer Chemother Pharmacol. 2019 Apr 24. doi: 10.1007/s00280-019-03830-5. [Epub ahead of print]

 

Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. Ma D1, Zhang Y2, Xing P1, et al. Thorac Cancer. 2019 May;10(5):1213-1219. doi: 10.1111/1759-7714.13071. Epub 2019 Apr 16.

 

Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Sonehara K1, Kobayashi T2, Tateishi K1, et al. Thorac Cancer. 2019 May;10(5):1078-1085. doi: 10.1111/1759-7714.13047. Epub 2019 Apr 20.

 

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Drilon A#1,2, Schoenfeld AJ#1, Arbour KC1, et al. Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003665. doi: 10.1101/mcs.a003665. Print 2019 Apr.

 

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Pavan A1,2, Calvetti L3, Dal Maso A1,2, et al. Oncologist. 2019 Apr 23. pii: theoncologist.2018-0563. doi: 10.1634/theoncologist.2018-0563. [Epub ahead of print]

 

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. Kuo CS1,2, Wang CC3, Huang YC4, et al. Thorac Cancer. 2019 May;10(5):1158-1166. doi: 10.1111/1759-7714.13057. Epub 2019 Apr 5.

 

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Mok TSK1, Wu YL2, Kudaba I3, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

 

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Shibaki R1, Murakami S1, Shinno Y1, et al. Thorac Cancer. 2019 Apr;10(4):815-822. doi: 10.1111/1759-7714.13004. Epub 2019 Feb 14.

 

Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies.

Taha T1, Meiri D2,3, Talhamy S3, Wollner M1, Peer A1, Bar-Sela G4,3. Oncologist. 2019 Apr;24(4):549-554. doi: 10.1634/theoncologist.2018-0383. Epub 2019 Jan 22.

 

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Shaw AT1, Riely GJ2, Bang YJ3, et al. Ann Oncol. 2019 Apr 13. pii: mdz131. doi: 10.1093/annonc/mdz131. [Epub ahead of print]

 

Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial. Michels S1, Massutí B2, Schildhaus HU3, et al. J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276-X. doi: 10.1016/j.jtho.2019.03.020. [Epub ahead of print]

 

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.

Zhang YC1, Chen ZH1, Zhang XC1, et al. EBioMedicine. 2019 Apr 23. pii: S2352-3964(19)30269-5. doi: 10.1016/j.ebiom.2019.04.030. [Epub ahead of print]

NSCLC - RADIOTHERAPY

Fiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study. Bowling MR1, Folch EE2, Khandhar SJ3,et al. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841234. doi: 10.1177/1753466619841234.

 

Radiotherapy for oligometastatic tumor improved the prognosis of patients with non-small cell lung cancer (NSCLC). Gong HY1, Wang Y1, Han G1, Song QB1. Thorac Cancer. 2019 May;10(5):1136-1140. doi: 10.1111/1759-7714.13054. Epub 2019 Apr 7.

 

Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer. Yan SX1, Qureshi MM2, Dyer M2, Truong MT2, Mak KS3. Lung Cancer. 2019 May;131:147-153. doi: 10.1016/j.lungcan.2019.03.031. Epub 2019 Apr 1.

 

Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes. Appel S1, Bar J2,3, Ben-Nun A3,4, et al. Br J Radiol. 2019 May;92(1097):20180960. doi: 10.1259/bjr.20180960. Epub 2019 Apr 1.

 

Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting. Mak RH1, Endres MG2,3, Paik JH2,4, et al. JAMA Oncol. 2019 Apr 18. doi: 10.1001/jamaoncol.2019.0159. [Epub ahead of print]

 

Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Elhammali A1, Blanchard P2, Yoder A1, Liao Z1, Zhang X3, Ronald Zhu X3, Allen PK1, Jeter M1, Welsh J1, Nguyen QN4. Radiother Oncol. 2019 Apr 17;136:136-142. doi: 10.1016/j.radonc.2019.03.029. [Epub ahead of print]

 

Re-irradiation in locally recurrent lung cancer patients. Schlampp I1,2,3, Rieber J4,5,6, Adeberg S4,5,6, et al. Strahlenther Onkol. 2019 Apr 1. doi: 10.1007/s00066-019-01457-2. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. Li H1, Zeng J2, Jin X1, Yu X1, Zhou G3, Hong W4. Cancer Chemother Pharmacol. 2019 Jun;83(6):1083-1090. doi: 10.1007/s00280-019-03823-4. Epub 2019 Apr 1.

 

Salvage surgery for small cell lung cancer after chemoradiotherapy. Nakanishi K1, Mizuno T1, Sakakura N1, Kuroda H1, Shimizu J2, Hida T2, Yatabe Y3, Sakao Y1. Jpn J Clin Oncol. 2019 Apr 1;49(4):389-392. doi: 10.1093/jjco/hyz010.

 

Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial. Chen J1, Liu B2, Zhang F2, Cui W2, Zhang P3. Cancer Chemother Pharmacol. 2019 Apr 30. doi: 10.1007/s00280-019-03828-z. [Epub ahead

 

Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.

Tay RY1, Fernández-Gutiérrez F2, Foy V2, et al. Ann Oncol. 2019 Apr 24. pii: mdz122. doi: 10.1093/annonc/mdz122. [Epub ahead of print]

 

Timing of treatment in small-cell lung cancer. Bhandari S1, Pham D2, Pinkston C3, Oechsli M2, Kloecker G2. Med Oncol. 2019 Apr 25;36(6):47. doi: 10.1007/s12032-019-1271-3.

 

Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models. Li QW1, Qiu B1, Wang B1, et al. Radiother Oncol. 2019 Apr 15;136:98-105. doi: 10.1016/j.radonc.2019.03.035. [Epub ahead of print]

 

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP).

Cardona AF1,2,3, Rojas L1,2,4, Zatarain-Barrón ZL5, et all. Front Oncol. 2019 Apr 17;9:254. doi: 10.3389/fonc.2019.00254. eCollection 2019.

 

Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics. Huang RSP, Holmes BF, Powell C, Marati RV, Tyree D, Admire B, Streator A, Newell AEH, Perez J, Dalvi D, ElGabry EA1.  Arch Pathol Lab Med. 2019 Apr 8. doi: 10.5858/arpa.2018-0497-OA. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Integrating early palliative care into routine practice for patients with cancer: A mixed methods evaluation of the INTEGRATE Project. Evans JM1,2, Mackinnon M1, Pereira J3,4,5,6,7, et al. Psychooncology. 2019 Apr 4. doi: 10.1002/pon.5076. [Epub ahead of print]

 

Loneliness as a mediator of the relationship of social cognitive variables with depressive symptoms and quality of life in lung cancer patients beginning treatment. Hyland KA1,2, Small BJ1,2, Gray JE1, et al. Psychooncology. 2019 Apr 1. doi: 10.1002/pon.5072. [Epub ahead of print]

 

New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. McFarland DC1. Gen Hosp Psychiatry. 2019 Apr 18. pii: S0163-8343(18)30503-6. doi: 10.1016/j.genhosppsych.2019.04.001. [Epub ahead of print]

 

A qualitative study of healthcare-related experiences of non-smoking women with lung cancer.

Dao D1, O’Connor JM2, Jatoi A3, Ridgeway J4, Deering E2, Schwecke A2, Breitkopf CR4, Huston O2, Le-Rademacher JG5. Support Care Cancer. 2019 Apr 15. doi: 10.1007/s00520-019-04759-4. [Epub ahead of print]

 

Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists.

Loh KP1, Mohile SG2, Lund JL3, et al. Oncologist. 2019 Apr 23. pii: theoncologist.2018-0890. doi: 10.1634/theoncologist.2018-0890. [Epub ahead of print]

 

Understanding Underuse of Advance Care Planning Among a Cohort of African American Patients With Advanced Cancer: Formative Research That Examines Gaps in Intent to Discuss Options for Care. Rhodes RL1,2, Ukoha NCE3, Williams KA4, et al. Am J Hosp Palliat Care. 2019 Apr 21:1049909119843276. doi: 10.1177/1049909119843276. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Banik K1, Ranaware AM2, Deshpande V2, et al. Pharmacol Res. 2019 Apr 17;144:192-209. doi: 10.1016/j.phrs.2019.04.004. [Epub ahead of print]

MISCELLANEOUS WORKS

Impact of the Hydraulic Fracturing on Indoor Radon Concentrations in Ohio: A Multilevel Modeling Approach. Xu Y1, Sajja M2, Kumar A2. Front Public Health. 2019 Apr 10;7:76. doi: 10.3389/fpubh.2019.00076. eCollection 2019.

 

Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory. Ostroff JS1, Riley KE1, Shen MJ2, Atkinson TM1, Williamson TJ1, Hamann HA3. Psychooncology. 2019 Feb 19. doi: 10.1002/pon.5033. [Epub ahead of print]

 

Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Remon J1, Ahn MJ2, Girard N3, Johnson M4, Kim DW5, Lopes G6, Pillai RN7, Solomon B8, Villacampa G9, Zhou Q10. J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30280-1. doi: 10.1016/j.jtho.2019.03.022. [Epub ahead of print]

 

Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. Lim SM1, Choi JW2, Hong MH3, et al. Lung Cancer. 2019 May;131:139-146. doi: 10.1016/j.lungcan.2019.04.002. Epub 2019 Apr 3.

Archives